Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

The company’s wide economic moat stems from its leadership position in the treatment of HIV, with products that are patented ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

While Gilead Sciences, Inc. (NASDAQ:GILD) possesses a strong position in HIV treatments, it remains focused on maintaining its market share via innovative products. Gilead Sciences, Inc. (NASDAQ ...

Shares of Super Micro Computer jumped after the company set a sales outlook for fiscal 2026 that blows past current Wall Street forecasts, unwinding a selloff earlier in the day.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.